SlideShare a Scribd company logo

12702889

•
•
J
James Hilbert

AMRN 11/4 nonfinal rejection patent

1 of 20
Download to read offline
12702889
12702889
12702889
12702889
12702889
12702889
12702889
12702889
12702889
12702889
12702889
12702889
12702889
12702889
12702889
12702889
12702889
12702889
12702889
12702889

Recommended

The combos study an expert interview with william s
The combos study an expert interview with william sThe combos study an expert interview with william s
The combos study an expert interview with william sJames Hilbert
 
GS Weekly Options Watch - May 11th
GS Weekly Options Watch - May 11thGS Weekly Options Watch - May 11th
GS Weekly Options Watch - May 11thJames Hilbert
 
Psti needham 4411
Psti needham 4411Psti needham 4411
Psti needham 4411James Hilbert
 
Inhx buy nov 2010
Inhx buy nov 2010Inhx buy nov 2010
Inhx buy nov 2010James Hilbert
 
Asco 2012 abstract_45010_oral_final
Asco 2012 abstract_45010_oral_finalAsco 2012 abstract_45010_oral_final
Asco 2012 abstract_45010_oral_finalJames Hilbert
 
$PSTI Oppenheimer
$PSTI Oppenheimer$PSTI Oppenheimer
$PSTI OppenheimerJames Hilbert
 
Rgen 101510
Rgen 101510Rgen 101510
Rgen 101510James Hilbert
 
Clda griffin01
Clda griffin01Clda griffin01
Clda griffin01James Hilbert
 

Recommended

The combos study an expert interview with william s
The combos study an expert interview with william sThe combos study an expert interview with william s
The combos study an expert interview with william sJames Hilbert
 
GS Weekly Options Watch - May 11th
GS Weekly Options Watch - May 11thGS Weekly Options Watch - May 11th
GS Weekly Options Watch - May 11thJames Hilbert
 
Psti needham 4411
Psti needham 4411Psti needham 4411
Psti needham 4411James Hilbert
 
Inhx buy nov 2010
Inhx buy nov 2010Inhx buy nov 2010
Inhx buy nov 2010James Hilbert
 
Asco 2012 abstract_45010_oral_final
Asco 2012 abstract_45010_oral_finalAsco 2012 abstract_45010_oral_final
Asco 2012 abstract_45010_oral_finalJames Hilbert
 
$PSTI Oppenheimer
$PSTI Oppenheimer$PSTI Oppenheimer
$PSTI OppenheimerJames Hilbert
 
Rgen 101510
Rgen 101510Rgen 101510
Rgen 101510James Hilbert
 
Clda griffin01
Clda griffin01Clda griffin01
Clda griffin01James Hilbert
 
Clda roth01
Clda roth01Clda roth01
Clda roth01James Hilbert
 
Ariad jeffries jan 2011
Ariad jeffries jan 2011Ariad jeffries jan 2011
Ariad jeffries jan 2011James Hilbert
 
Second or third additional chemotherapy drug for non-small cell lung cancer i...
Second or third additional chemotherapy drug for non-small cell lung cancer i...Second or third additional chemotherapy drug for non-small cell lung cancer i...
Second or third additional chemotherapy drug for non-small cell lung cancer i...James Hilbert
 
$SNGX Nnational.2.1.2010
$SNGX Nnational.2.1.2010$SNGX Nnational.2.1.2010
$SNGX Nnational.2.1.2010James Hilbert
 
Mt200833a
Mt200833aMt200833a
Mt200833aJames Hilbert
 
Protalix analyst day presentation
Protalix analyst day presentationProtalix analyst day presentation
Protalix analyst day presentationJames Hilbert
 
$MAPP Phase 3 results
$MAPP Phase 3 results$MAPP Phase 3 results
$MAPP Phase 3 resultsJames Hilbert
 
5 understanding some basic trial designs in sarcomas (inclusive a placebo one...
5 understanding some basic trial designs in sarcomas (inclusive a placebo one...5 understanding some basic trial designs in sarcomas (inclusive a placebo one...
5 understanding some basic trial designs in sarcomas (inclusive a placebo one...James Hilbert
 
Aldoxorubicin p2-sts-01 ctos poster 10-31-13
Aldoxorubicin p2-sts-01 ctos poster 10-31-13Aldoxorubicin p2-sts-01 ctos poster 10-31-13
Aldoxorubicin p2-sts-01 ctos poster 10-31-13James Hilbert
 
Ttrsc
TtrscTtrsc
TtrscJames Hilbert
 
Alny
AlnyAlny
AlnyJames Hilbert
 
Company presentation
Company presentationCompany presentation
Company presentationJames Hilbert
 
Transforming time for prostate cancer therapies
Transforming time for prostate cancer therapiesTransforming time for prostate cancer therapies
Transforming time for prostate cancer therapiesJames Hilbert
 
1 s2.0-s1470204510701327-main
1 s2.0-s1470204510701327-main1 s2.0-s1470204510701327-main
1 s2.0-s1470204510701327-mainJames Hilbert
 
Phase 2b emerge study of cdx 011
Phase 2b emerge study of cdx 011Phase 2b emerge study of cdx 011
Phase 2b emerge study of cdx 011James Hilbert
 
Bmn 110 ph12 results
Bmn 110 ph12 resultsBmn 110 ph12 results
Bmn 110 ph12 resultsJames Hilbert
 
Novel therapies in hcc
Novel therapies in hccNovel therapies in hcc
Novel therapies in hccJames Hilbert
 
Nsclc 2nd line
Nsclc 2nd lineNsclc 2nd line
Nsclc 2nd lineJames Hilbert
 
Docetaxel Versus Docetaxel/Cisplatin in NSCLC
Docetaxel Versus Docetaxel/Cisplatin in NSCLCDocetaxel Versus Docetaxel/Cisplatin in NSCLC
Docetaxel Versus Docetaxel/Cisplatin in NSCLCJames Hilbert
 
Cbli 2011 05 25 barda
Cbli 2011 05 25 bardaCbli 2011 05 25 barda
Cbli 2011 05 25 bardaJames Hilbert
 
Optr 04052011
Optr 04052011Optr 04052011
Optr 04052011James Hilbert
 
Lovenox trial scheduling
Lovenox trial schedulingLovenox trial scheduling
Lovenox trial schedulingJames Hilbert
 

More Related Content

Viewers also liked

Ariad jeffries jan 2011
Ariad jeffries jan 2011Ariad jeffries jan 2011
Ariad jeffries jan 2011James Hilbert
 
Second or third additional chemotherapy drug for non-small cell lung cancer i...
Second or third additional chemotherapy drug for non-small cell lung cancer i...Second or third additional chemotherapy drug for non-small cell lung cancer i...
Second or third additional chemotherapy drug for non-small cell lung cancer i...James Hilbert
 
$SNGX Nnational.2.1.2010
$SNGX Nnational.2.1.2010$SNGX Nnational.2.1.2010
$SNGX Nnational.2.1.2010James Hilbert
 
Protalix analyst day presentation
Protalix analyst day presentationProtalix analyst day presentation
Protalix analyst day presentationJames Hilbert
 
$MAPP Phase 3 results
$MAPP Phase 3 results$MAPP Phase 3 results
$MAPP Phase 3 resultsJames Hilbert
 
5 understanding some basic trial designs in sarcomas (inclusive a placebo one...
5 understanding some basic trial designs in sarcomas (inclusive a placebo one...5 understanding some basic trial designs in sarcomas (inclusive a placebo one...
5 understanding some basic trial designs in sarcomas (inclusive a placebo one...James Hilbert
 

Viewers also liked (8)

Clda roth01
Clda roth01Clda roth01
Clda roth01
 
Ariad jeffries jan 2011
Ariad jeffries jan 2011Ariad jeffries jan 2011
Ariad jeffries jan 2011
 
Second or third additional chemotherapy drug for non-small cell lung cancer i...
Second or third additional chemotherapy drug for non-small cell lung cancer i...Second or third additional chemotherapy drug for non-small cell lung cancer i...
Second or third additional chemotherapy drug for non-small cell lung cancer i...
 
$SNGX Nnational.2.1.2010
$SNGX Nnational.2.1.2010$SNGX Nnational.2.1.2010
$SNGX Nnational.2.1.2010
 
Mt200833a
Mt200833aMt200833a
Mt200833a
 
Protalix analyst day presentation
Protalix analyst day presentationProtalix analyst day presentation
Protalix analyst day presentation
 
$MAPP Phase 3 results
$MAPP Phase 3 results$MAPP Phase 3 results
$MAPP Phase 3 results
 
5 understanding some basic trial designs in sarcomas (inclusive a placebo one...
5 understanding some basic trial designs in sarcomas (inclusive a placebo one...5 understanding some basic trial designs in sarcomas (inclusive a placebo one...
5 understanding some basic trial designs in sarcomas (inclusive a placebo one...
 

More from James Hilbert

Aldoxorubicin p2-sts-01 ctos poster 10-31-13
Aldoxorubicin p2-sts-01 ctos poster 10-31-13Aldoxorubicin p2-sts-01 ctos poster 10-31-13
Aldoxorubicin p2-sts-01 ctos poster 10-31-13James Hilbert
 
Company presentation
Company presentationCompany presentation
Company presentationJames Hilbert
 
Transforming time for prostate cancer therapies
Transforming time for prostate cancer therapiesTransforming time for prostate cancer therapies
Transforming time for prostate cancer therapiesJames Hilbert
 
1 s2.0-s1470204510701327-main
1 s2.0-s1470204510701327-main1 s2.0-s1470204510701327-main
1 s2.0-s1470204510701327-mainJames Hilbert
 
Phase 2b emerge study of cdx 011
Phase 2b emerge study of cdx 011Phase 2b emerge study of cdx 011
Phase 2b emerge study of cdx 011James Hilbert
 
Bmn 110 ph12 results
Bmn 110 ph12 resultsBmn 110 ph12 results
Bmn 110 ph12 resultsJames Hilbert
 
Novel therapies in hcc
Novel therapies in hccNovel therapies in hcc
Novel therapies in hccJames Hilbert
 
Docetaxel Versus Docetaxel/Cisplatin in NSCLC
Docetaxel Versus Docetaxel/Cisplatin in NSCLCDocetaxel Versus Docetaxel/Cisplatin in NSCLC
Docetaxel Versus Docetaxel/Cisplatin in NSCLCJames Hilbert
 
Cbli 2011 05 25 barda
Cbli 2011 05 25 bardaCbli 2011 05 25 barda
Cbli 2011 05 25 bardaJames Hilbert
 
Lovenox trial scheduling
Lovenox trial schedulingLovenox trial scheduling
Lovenox trial schedulingJames Hilbert
 
Dcth isolation perfusion
Dcth isolation perfusionDcth isolation perfusion
Dcth isolation perfusionJames Hilbert
 
Astm restore cli update nov 2010
Astm restore cli update nov 2010Astm restore cli update nov 2010
Astm restore cli update nov 2010James Hilbert
 

More from James Hilbert (17)

Aldoxorubicin p2-sts-01 ctos poster 10-31-13
Aldoxorubicin p2-sts-01 ctos poster 10-31-13Aldoxorubicin p2-sts-01 ctos poster 10-31-13
Aldoxorubicin p2-sts-01 ctos poster 10-31-13
 
Ttrsc
TtrscTtrsc
Ttrsc
 
Alny
AlnyAlny
Alny
 
Company presentation
Company presentationCompany presentation
Company presentation
 
Transforming time for prostate cancer therapies
Transforming time for prostate cancer therapiesTransforming time for prostate cancer therapies
Transforming time for prostate cancer therapies
 
1 s2.0-s1470204510701327-main
1 s2.0-s1470204510701327-main1 s2.0-s1470204510701327-main
1 s2.0-s1470204510701327-main
 
Phase 2b emerge study of cdx 011
Phase 2b emerge study of cdx 011Phase 2b emerge study of cdx 011
Phase 2b emerge study of cdx 011
 
Bmn 110 ph12 results
Bmn 110 ph12 resultsBmn 110 ph12 results
Bmn 110 ph12 results
 
Novel therapies in hcc
Novel therapies in hccNovel therapies in hcc
Novel therapies in hcc
 
Nsclc 2nd line
Nsclc 2nd lineNsclc 2nd line
Nsclc 2nd line
 
Docetaxel Versus Docetaxel/Cisplatin in NSCLC
Docetaxel Versus Docetaxel/Cisplatin in NSCLCDocetaxel Versus Docetaxel/Cisplatin in NSCLC
Docetaxel Versus Docetaxel/Cisplatin in NSCLC
 
Cbli 2011 05 25 barda
Cbli 2011 05 25 bardaCbli 2011 05 25 barda
Cbli 2011 05 25 barda
 
Optr 04052011
Optr 04052011Optr 04052011
Optr 04052011
 
Lovenox trial scheduling
Lovenox trial schedulingLovenox trial scheduling
Lovenox trial scheduling
 
Dcth isolation perfusion
Dcth isolation perfusionDcth isolation perfusion
Dcth isolation perfusion
 
Clda bmo01
Clda bmo01Clda bmo01
Clda bmo01
 
Astm restore cli update nov 2010
Astm restore cli update nov 2010Astm restore cli update nov 2010
Astm restore cli update nov 2010